Navigation Links
Deflazacort in Duchenne Muscular Dystrophy
Date:3/24/2016

LONDON, March 24, 2016 /PRNewswire/ --

US Neurology, the peer-reviewed journal, has published an article summarizing the benefits and risks of deflazacort in Duchenne muscular dystrophy.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

Duchenne muscular dystrophy (DMD) is a devastating disorder that is the most common and severe form of childhood onset muscular dystrophy. While guidelines exist that promote a multidisciplinary approach to treatment of DMD, surveys have identified inconsistent adherence to the recommendations. This is particularly highlighted by the variability in the prescriptive habits of corticosteroids, which have a long history of literature supporting their use in DMD. Relatively recent publications have uncovered differences between countries in the prescription patterns of steroid regimens. Currently, treatment recommendations lack comparative data on the efficacy and safety of alternative dosing regimens of corticosteroids. New research is being conducted to help understand the benefits and risks of the most commonly used glucocorticoid regimens in DMD. Deflazacort is a glucocorticoid corticosteroid that is currently seeking approval in the U.S. This article summarizes the relevant published literature on deflazacort to help inform DMD-treating physicians on its impact on the disease.

The full peer-reviewed, open-access article is available here:

href="http://doi.org/10.17925/USN.2016.12.01.17" rel="nofollow">http://doi.org/10.17925/USN.2016.12.01.12

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
+44 (0) 207 193 6093
managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.



'/>"/>
SOURCE Touch Medical Media
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
2. New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
3. PPMD to Lead Duchenne Community in Developing Draft Guidance to Accelerate Drug Development and FDA Review
4. PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy
5. Expected Launch of First Disease-Modifying Therapies Through 2023 Will Revolutionize Treatment of Duchenne Muscular Dystrophy
6. ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy
7. Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
8. EspeRares Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy
9. Global Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Market 2015 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
10. Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
11. Global Duchenne Muscular Dystrophy Drugs Market 2015-2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... ... August 11, 2018 , ... Lefty’s the Left Hand ... games and gifts. Left-Handers are possibly the world’s largest silent minority. Fully10% of ... of prejudice, countless indignities and inconveniences, left-handers quietly learn to “adapt”without whining or ...
(Date:8/9/2018)... , ... August 09, 2018 , ... Autism is a ... others. Given how widespread autism is, (approximately 1 in 68 people have the disorder), ... there are options to help teach a child with autism methods of communication and ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Charlotte-area company cbdMD named the exclusive sponsor. , “We’re honored to have been ... such public embrace for CBD on a national level,” said cbdMD’s Chief Scientific ...
Breaking Medicine Technology:
(Date:8/11/2018)... Texas (PRWEB) , ... August 10, 2018 , ... Dr. ... recently traveled to Asunción, Paraguay for a week-long international outpost trip to deliver dental ... affiliated colleagues and support staff, Dr. Eftekhari volunteered his time to help deliver ...
(Date:8/9/2018)... ... 2018 , ... Thousands of US women with FDA-approved silicone ... from The American Society of Plastic Surgeons (ASPS), The American Society for Aesthetic ... As an MRI is recommended by FDA after the first three years then ...
(Date:8/9/2018)... , ... August 09, 2018 , ... ... and Kathy Coover and the company’s independent distributors, customers, and employees, the newly ... hours of fundraising, exceeding the $2 million goal. 100 percent of the donations ...
(Date:8/3/2018)... ... 03, 2018 , ... Firstaid4sport have been successfully selling Mueller ... Firstaid4sport business in the 1990's and his son in law, Michael Davison has ... in the UK of sports medicine products, supplying professional and amateur sports teams ...
(Date:8/2/2018)... ... August 02, 2018 , ... Allegheny Health Network ... clinicians inside and outside the network to vital patient imaging exams, saving valuable ... joins other leading hospital systems nationwide in using lifeIMAGE, which expands access to ...
Breaking Medicine News(10 mins):